Bob. And everyone. you, call thank joining you afternoon, for our Good Thank on today.
for I'll on of call, quarter as accomplishment fourth the in well in the During XXXX. as plans our our focus growth XXXX,
and very financial successful new a today's We two we government to a our XXXX. strengthened fourth saw press from you had quarter closed As with completed finish customers. positions release, acquisitions, contracts strong on
assume monoclonal prophylaxis supply of Raxibacumab In multiyear the to with fully and of anthrax. contract treatment by responsibility the through completed BARDA a First, SNS acquisition the a we antibody This for product recent from GSK. to for FDA is November October, our the XXXX. the human inhalational acquisitions. We product approved
our ACAMXXXX October, to Sanofi. value the remaining quarter this of of million we and the of included is world, fill/finish last On we SNS. the of product capabilities. manufacturing the a business manufacturing to the in a And for license ACAMXXXX the contract CDC and viral contract completed delivery live strengthen with closing vaccine which acquisition up had Smallpox began and year the XX fourth expand only $XXX In deliveries This in FDA ACAMXXXX facility approximately date, from the an also acquisition year. that
had $XXX this of million. date, up remaining closing a approximately to contract value the On
With in we quarter the year. facility, November, began manufacturing fourth approval Canton product the FDA in our last deliveries of
We be Raxibacumab and key and expect in beyond. contributors growth ACAMXXXX to both to our XXXX
lower presentation. the discuss converted that shortly notes Bob This quarter, also of less borrowing $XXX we acquisitions. with this million us replaced an after in to our facility we covenant. during During credit to effectively strengthened includes with existing at We in to outstanding. capital all actions new a cost convertible and which our position. through a greater position fourth had pursue These that will senior enhanced growth financial capacity and we stringent detail facility substantially $XXX growth the million credit strategy his follow provide up collectively
two Finally, in base customer we our our expanded and sales. the awards fourth that government quarter secured new contract product diversified
product increased for of the the our it sale US platform, it product. by were at contract portfolio of up and an auto-injector supply and a broadens to emergency TROBIGARD, shows TROBIGARD auto-injector it designed overall the significant first we our agent US a This valued State demand government administration represents of our Department that measure. value device for government. of million counter self First, is this awarded to to $XX It customers confirms use unique of contract nerve
the regulations. new the contract product inhalational Globulin extraordinary of Department the contract approval Health by government the for of was Anthrasil recent the Anthrasil Canadian award Anthrax quarter of awarded fourth under supply signed Immune anthrax. This drug second its Defense treatment The use by National or followed of in Canada for
So, We in and and continued successful customer our enhance towards diversified our to to product goals. our quarter. base, advance executed very expanded in ended fourth financial we and portfolio XXXX look continue strategy, had our poised year year position and XXXX. productive for summary, This forward on the a we growth
under closer our product marketed our across to product and we of milestones revenue on Specifically, year that to expect to BioThorx we our driven achieve anti-infective our contract increase by look services, marketed a continued with continue we from at several will our expect the pipeline and And revenues be execute services, significant factors. CDC. Taking strategy. the current our five derived our deliveries expect and development vaccines product SNS growth and business, growth
ACAMXXXX measure contract, current to Raxibacumab that ensure deliveries product while Bayview we In then follow supply contract side. completing addition, SNS. of expect under multiyear facility we for to the under negotiating of continue uninterrupted the key thereby business, manufacturing and advancing our to of anchor contract therapeutic Raxibacumab a counter existing transfer an our tech providing BARDA deliveries anticipate our our a In this multiyear critical on antibiotic to
anticipate BAT customers and VIG our we will Anthrasil, of the addition, to that deliveries growth. to In existing contribute and revenue potentially overall new
to with continue and in to targeted by Department recently under multiyear the device of be our Turning driven business. our announced our State expansion contract, international delivery DoD the under Revenues contract TROBIGARD orders of will markets. RSDL
annual of product we and the improved and by manufacturing market contribution to expect business is the an capabilities. CMO Growth full facilities Finally, our and increase from our capabilities. significant of concept driven utilization development manufacturing broader capacity suite in demand, in revenue a portfolio business leveraging global
our we targeting a development product are I number across earlier, As pipeline. milestones significant mentioned of
successful, and emergency authorization the First, for FDA procure this this and XXXX billion. are for process validated next working a enable delivery of year in remaining development application for manufacturing of BARDA existing to validation new expect NuThrax the been designation to an with to would use we our vaccine. methods. package. SNS the our to Steps the generation completed We've closely up under contract NuThrax, on file BARDA a procurement If the Anthrax to development with EUA $X.X be analytical
We this to we X package review months. expect FDA to are of FDA between time and targeting the late year, submitting this X an
several developed been for study. have our XXXX. influenza marketed are managing If we a targeting is and The hospitalized particularly this serious anti-influenza human months completing influenza has product study hyperimmune in the year this as which have several January, therapeutic we This an antibody infectious and or outbreak data developed by successful late our the pipeline candidate planned, nature licensed. of as at enrollment made intravenous platform FLU-IGIV, product and illness expect caused by Looking past seriousness of patients. in over immunoglobulin established Phase timely infection widespread X being our disease, early patient initiated on in used we to treatment
on in first efforts Zika quarter. the focused to our Turning
co-developing We or Phase X a for to on available this expect If of initiate are a to counter validated important in manufacturing DLAXXXX, our we as XXXX licensed data from based trial Zika we planned, early X be vaccine vaccine candidate XXXX. measure. Phase late occurs we expect enrollment our currently are candidate that Valneva and technology Zika
a initiating This is virus developed established Zika our in advance to using therapeutic clinic plan trial IG, hyperimmune also being X into immunoglobulin product Zika by the platform. our human XXXX. clinical candidate also our We Phase
product fast granted Importantly, track candidate FDA. by last was the designation December the
We contract a the of for delivery BARDA spray formative and are plans cyanide well poisoning. projects for we to nasal also two year DoD. multi One the to underway. treatment of underway number development other be have auto this Both injected device was Last develop for device completed nerve-agent we human development antidote an the programs awards. studies auto-injector for contract a the drug antidote announced for for factor intern have year. the a And acute of
counter the development measure drug to device and of drug have project actively for options. a formulation for are for Additionally, multiple underway market drug we a combination chemical exploring development additional auto-injector adaptable single opportunities
achieve candidates of in It development in our with development summary, pipeline least a well significantly in to product our to closer brings four XXXX goal positioned at of advanced residual XXXX So, candidates with least three believe the six goal at anticipated we of candidates, development. product markets. advance we also progress are our
and within term, a months In our threats focus provides opportunities closing. applications. short year that will potential we business acquisitions market executing accretive Finally, few we health emerging product on of in in set continue and acquisition interest particular the market comments on for generate the of infectious public near CBRNe on including threats be goal With This revenue dual that and the strategy. diseases. acquisition a XX to
of term the call longer of for this time opportunities. M&A an Emergent. our for transaction year believe towards the Kramer is to is While our we exciting timing over and I progress remarks. I'll can as enhance our forward mission financial now turn goals achieve to we concludes uncertain, That my any work life. updating prepared This the throughout to given our and look of on pipeline details our Bob? always on protect you target we Bob performance. fulfillment the goal
